Loni Da Silva

Loni joined EyeBio as Chief Regulatory Officer in 2023. She is responsible for overseeing overall compliance across the organization and communicating with regulatory authorities as clinical trials advance.

In 2022, Loni was named one of the top 25 healthcare technology leaders of Miami. She has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 25 years in the ophthalmic therapeutic space. She began her career at Hoffman La-Roche, and most recently served as SVP of Global Regulatory Affairs for Oyster Point Pharma. Loni has led global regulatory affairs for four start-ups and IPOs including Eyetech, Pharmasset, IVERIC bio (formerly Ophthotech Corporation), and Oyster Point Pharma, and has consulted for many ophthalmic companies in a variety of ophthalmic indications including wet and dry AMD and dry eye disease. In addition to the ophthalmic space, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology.

Loni received her B.S. in Microbiology from Penn State University and an M.S. in Regulatory Affairs from Long Island University. She is also RAC certified.